Gene+ and NeoCura Announce Strategic Collaboration to Advance Clinical Development of mRNA Tumor Neoantigen Vaccines

Recently,Gene+ and NeoCura Bio-Medical Technology Co., Ltd. Sign Strategic Cooperation Agreement in BeijingBoth parties reached a consensus: NeoCura will fully utilize Gene+'s testing platform technology to accelerate the early clinical trial progress of mRNA tumor neoantigen vaccines. Gene+ will leverage the advantages of its sequencing platform in performance, application, and data security to jointly promote precision oncology treatment and build a new ecosystem for industry chain cooperation.

Gene+ CEO Yi Xin and NeoCura Co-founder & CEO Wang Yi Sign Agreement on Behalf of Their Companies

As a high-tech enterprise specializing in AI + RNA drug research and development, NeoCura has consistently maintained a leading position in the field of RNA innovative drug R&D. Leveraging its own R&D experience and technical advantages, NeoCura has successively conducted in-depth research in multiple directions, including mRNA tumor vaccines, tumor microenvironment immunomodulation, and viral vaccines. Gene+, an innovative high-tech company focusing on precision medicine, has built a strong reputation in the pharmaceutical services sector with its extensive project experience in scientific research, comprehensive solutions based on China-produced sequencing platforms, and a testing system that meets the standards for clinical drug trials. Based on the promising and forward-looking technology of mRNA tumor vaccines, both parties can complement each other's strengths in the clinical transformation and application process to achieve mutual benefits.

Gene+ CEO Yi Xin stated:

Gene+ attaches great importance to testing needs in the drug development process. The company has currently established a testing and delivery system that complies with drug clinical trial regulations, capable of simultaneously meeting the high-standard requirements of preclinical scientific research exploration and compliant clinical trial testing, assisting in the standardized conduct of clinical trials and drug market entry.Gene+ continuously pursues technological innovation and product iteration, leveraging the advantages of a multi-omics platform to assist NeoCura in neoantigen prediction, validation, and process optimization, and to expand higher value space in future collaborations.Going forward, the company will continue to pursue perfection, exploring shorter tumor detection cycles to provide more stable, reliable, and compliant testing services for NeoCura and other partners, achieving mutual benefit of resources and common development within the industry.

NeoCura Co-founder & CEO Wang Yi stated:

We are very pleased to establish a partnership with Gene+. NeoCura has been actively applying cutting-edge emerging technologies such as multi-omics and AI algorithms to empower the R&D of RNA innovative drugs. Gene+ possesses industry-leading high-throughput genetic testing technology and is expanding its application in the field of cancer treatment.We look forward to complementing each other's strengths with Gene+, using advanced AI algorithm platforms and high-throughput gene sequencing technology to continuously enrich tumor genomic big data and accelerate the clinical trial process of NeoCura's mRNA tumor neoantigen vaccine.In the future, NeoCura will collaborate with more industry peers to provide patients with safe and effective innovative drugs, contributing to the realization of "Healthy China."

About Gene+

Gene+ was founded in 2015 as an innovative high-tech enterprise born under the broader context of precision medicine. The company adheres to a strategy of indigenous development in China, leveraging large-scale platforms for testing, manufacturing, and data as its foundation. It provides gene detection products and services across three major business areas: medical, scientific, and health. This enables Gene+ to achieve a developmental path marked by technological breakthroughs, academic leadership, product innovation, and market leadership.

In the pharmaceutical services field, Gene+ provides testing products and services throughout the entire chain of drug development and commercialization, including preclinical target discovery, central laboratory testing and patient recruitment, companion diagnostic (CDx) development and commercialization, post-marketing promotion, etc. With rich project experience and technical qualifications, Gene+ has currently collaborated with over 60 well-known domestic and international pharmaceutical companies, participated in more than 200 clinical trial projects, and achieved multiple high-quality research成果转化.

About NeoCura

NeoCura is a high-tech enterprise that relies on AI technology to focus on the research and development of innovative RNA drugs. It has built a multi-omics big data collection platform and a multi-layered biological omics database, using AI and bioinformatics technology for in-depth drug target mining and fully automated drug design for the development of innovative RNA drugs.

The company has gathered a top-tier scientific research team with a global perspective, comprising experts in various fields such as AI bioinformatics, tumor immunology, novel vaccine development, drug delivery, and nucleic acid vectors. Its R&D pipeline covers multiple directions including cancer vaccines, tumor microenvironment immunomodulators, and viral vaccines. It has established leading RNA drug R&D and production centers in Beijing, Shenzhen, and Guangzhou, China, supporting pipeline R&D, technological upgrades, and clinical research.

To date, XH101 Injection, the world's first mRNA tumor neoantigen vaccine with a globally pioneering target independently developed by NeoCura, has been accepted by the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA), placing the company at the forefront of industry innovation.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message to the WeChat Official Account or send a message, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank You for Your Support. We Look Forward to Your Feedback.

Scan the QR code to provide valuable suggestions